Momenta Pharmaceuticals (MNTA) Receives Price Target

Momenta Pharmaceuticals (MNTA) : The highest level Momenta Pharmaceuticals (MNTA) is projected to reach is $20 for the short term and the lowest estimate is at $13. The consolidated price target from 6 rating analysts who initiate coverage on the stock is $15.67 and the possibility the share price can swing is $3.08.

Momenta Pharmaceuticals (MNTA) : 7 analysts are covering Momenta Pharmaceuticals (MNTA) and their average rating on the stock is 1.86, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Also, JP Morgan maintains their rating on the shares of Momenta Pharmaceuticals (NASDAQ:MNTA). The current rating of the shares is Overweight. Equity Analysts at the Firm lowers the price target to $15 per share from $21 per share. The rating by the firm was issued on August 5, 2016.

Momenta Pharmaceuticals (NASDAQ:MNTA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $12.01 and $11.79 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $12.49. The buying momentum continued till the end and the stock did not give up its gains. It closed at $12.15, notching a gain of 1.08% for the day. The total traded volume was 870,761 . The stock had closed at $12.02 on the previous day.

Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Companys product, a generic version of Lovenox (enoxaparin sodium injection), was approved by the United States Food and Drug Administration. The Company is developing Complex Generics, such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars, including M923 and M834. The Company is developing Novel Therapeutics, including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923, a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.